Drug
Pegylated Interferon Alfa 2A
Pegylated Interferon Alfa 2A: highest development phase Phase 3, developed by Vertex Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Vertex Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pegylated Interferon Alfa 2a NCT00627926 | Phase 3 | Hepatitis C |
Latest
No recent events.
Follow Pegylated Interferon Alfa 2A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.